

All sponsors have provided sponsorship towards this independent programme. Sponsors have had no input into the content of the programme or the choice of speakers and have provided sponsorship monies used towards the meeting costs. Sponsors will have the opportunity to exhibit with a company stand during the meeting.

Premium Sponsors



Standard Sponsors



UK Myeloma Society Spring Day

Optimising Outcomes in Myeloma

Wednesday 19th March 2025

Hybrid Event from the Cavendish Conference Centre
22 Duchess Mews, London W1G 9DT

Register to attend in person or watch a live stream

Joint Chairs: **Dr Mamta Garg** (University Hospitals of Leicester)
Dr Jennifer Travers (Beatson West of Scotland Cancer Centre)

09.00 *Registration, coffee & exhibition*

09.30 UK practice updates

Dr Ceri Bygrave
University Hospital of Wales

09.50 UK trials updates

Dr Rakesh Popat
University College London Hospitals

Minimal Residual Disease (MRD) Testing in Multiple Myeloma

10.05 Mass spectrometry

Dr Hannah Giles
University Hospitals Birmingham

10.20 Flow cytometry

Dr Roger Owen
Leeds Teaching Hospitals

10.35 Next generation sequencing

Dr Angela Hamblin
Oxford University Hospitals

10.50 Is there a role for MRD in the UK?

Dr Karthik Ramasamy
Oxford University Hospitals

11.10 Audience vote and panel discussion

11.25 *Coffee break & exhibition*

IMS / ASH Bursary Winners

11.55 Progression from smouldering myeloma to myeloma is accompanied by an increase in CD56 bright bone marrow resident NK cells with reduced NK cell cytotoxic capacity

Dr Elise Rees
UCL Cancer Institute

12.05 Tolerability and clinical activity of novel first-in-class oral agent, inobrodib (CCS1477), in combination with polidomide and dexamethasone in relapsed/refractory multiple myeloma

Dr Emma Searle
The Christie Hospital, Manchester

12.15 Automated body composition analyses reveal significant associations with mortality in myeloma patients following immunotherapy with bispecific antibodies

Dr Charles Agbuduwe
Imperial College London

12.25 *Lunch, networking & exhibition*

Michael Morley Lecture

13.25 Results from the Iceland screens, treats or prevents multiple myeloma (iStopMM) study

Professor Sigurður Kristinnsson
University of Iceland

14.25 *Coffee break*

Goals of Myeloma Therapy

14.55 Case presentations and voting

15.05 Aims of induction therapy in fit myeloma patients

Professor Kwee Yong
University College London

15.30 Aims of induction therapy in frail myeloma patients

Dr Charlotte Pawlyn
Institute of Cancer Research UK

15.55 Aims of therapy in relapsed and refractory myeloma

Dr Matthew Jenner
University Hospital Southampton

16.20 Panel discussion

16.30 *Close*

Registration:

Standard Fee (until 4 March)
£75 (£50 for Scientists, Nurses & Pharmacists)

Late Fee (from 5 March)
£125 (£85 for Scientists, Nurses & Pharmacists)

[Registration now open at www.collaborativeconferences.co.uk/ukmsociety](http://www.collaborativeconferences.co.uk/ukmsociety)

*Online registration for this meeting is for healthcare professionals only
Please indicate if you wish to attend in person or watch the live stream while completing the registration form*

Enquiries: Please contact Alex - alex@collaborativeconferences.co.uk

The UK Myeloma Society exists to improve the care of myeloma patients through education and the promotion of trials

Premium Sponsors



Standard Sponsors



All sponsors have provided sponsorship towards this independent programme. Sponsors have had no input into the content of the programme or the choice of speakers and have provided sponsorship monies used towards the meeting costs. Sponsors will have the opportunity to exhibit with a company stand during the meeting.